FGP
EVH icon

Freestone Grove Partners’s Evolent Health EVH Stock Holding History

Freestone Grove Partners’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-122,696
Closed -$491K – 1049
2025
Q4 		$491K Buy
+122,696
New +$682K ﹤0.01% 575
2025
Q3 		– Sell
-491,621
Closed -$5.54M – 763
2025
Q2 		$5.54M Buy
+491,621
New +$4.52M 0.04% 320

Other funds holding EVH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
RF
Rubicon Founders Nashville, Tennessee $196M AUM 53.12% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $327M AUM 22.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Freestone Grove Partners's EVH Position: Q1 2026 in Review

Freestone Grove Partners sold out of Evolent Health (EVH) in Q1 2026, closing a stake of 122,696 shares — an estimated $491K sold.

Freestone Grove Partners first reported a position in EVH in Q2 2025 and held it in 2 quarters. The position peaked at $5.54M in Q2 2025. 192 funds tracked by Wall St. Rank hold EVH as of Q1 2026.

  • Freestone Grove Partners reported no remaining Evolent Health position as of Q1 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 122,696 Evolent Health shares in Q1 2026, an estimated $491K.
  • Freestone Grove Partners first reported a position in Evolent Health in Q2 2025 and held it in 2 quarters.
  • Freestone Grove Partners's Evolent Health position peaked at $5.54M in Q2 2025.
  • 192 funds tracked by Wall St. Rank held Evolent Health as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.